AUTHORS
Christina Maria Jurotich, BS, Jeong-Ah Kim, PhD2, Siqi Shen, PhD3, Kirby D. Johnson, PhD4, Sunduz Keles, PhD5, Emery Bresnick, PhD6
AFFILIATIONS
1 University of Wisconsin - Madison, Madison, Wisconsin, United States
2 University of Wisconsin - Madison, Madison, Wisconsin, United States
3 University of Wisconsin - Madison, Madison, Wisconsin, United States
4 University of Wisconsin - Madison, Madison, Wisconsin, United States
5 University of Wisconsin - Madison, Madison, Wisconsin, United States
6 University of Wisconsin - Madison, Madison, Wisconsin, United States
ABSTRACT
Germline genetic variation in human DDX41 is the most frequent variation implicated in predisposing to myelodysplastic syndromes and acute myeloid leukemia. Over 600 DDX41 missense variants have been reported in ClinVar, with more being discovered through mass population genome sequencing efforts. The majority (80-90%) of these are variants of uncertain significance, which confounds clinical decision-making. DDX41 encodes a multi-functional RNA-dependent ATPase regulating RNA splicing, the innate immune cGAS-STING pathway, genome stability, and is essential for hematopoiesis. Splicing factors have critical roles in regulating stem and progenitor cell state transitions. Mutations in genes encoding splicing factors, including SRSF2, SF3B1, ZRSR2, and DDX41, disrupt pre-mRNA splicing, predisposing to and/or promoting myeloid neoplasms. DDX41-associated pathologies can involve ineffective erythropoiesis, erythroid dysplasia reflecting abnormal erythrocyte development, and increased susceptibility to acquiring bi-allelic somatic variation in DDX41. Despite many variants altering conserved DDX41 domains, how most variants impact DDX41 functions globally and confer pathogenesis is unknown. We innovated genetic rescue systems to discriminate pathogenic from benign DDX41 variants and elucidated mechanisms governing DDX41 function in hematopoietic progenitor cells (Kim et al. Leukemia 2023; Kim et al. Nature Commun. 2025).
In myeloid progenitors, we discovered DDX41 regulates a cohort of RNAs via multiple alternative splicing events. Global analyses revealed two pathogenic variants, G173R and K331del, abrogated DDX41 splicing activities. R525H, the common somatic variant, retained partial activity (Kim et al. Nature Commun. 2025). We extended this analysis to compare DDX41 regulation in erythroid progenitors. We generated Ddx41-heterozygous G1E-ER-GATA1 (pro-erythroblast-like cells) clonal lines expressing ~50% lower levels of DDX41 RNA and protein. G1E-ER-GATA1-Ddx41+/- cells were infected with retrovirus expressing GFP, or GFP and DDX41 (WT, G173R, or K331del), GFP+ cells were sorted, and total RNA was analyzed by RNA-seq. Differential transcript usage (DTU) and expression (DTE) analyses revealed DDX41 regulated the alternative splicing of 590 transcript isoforms (padj<0.05), with 144 (24%) regulated in myeloid progenitors. Pathogenic variants lost ~90% of transcript-regulatory activities. Extension to human erythroid progenitors and iPSCs revealed conserved regulation of at least two transcript isoforms. The DDX41-regulated RNAs include a broad cadre of mRNAs and non-coding RNAs, including lncRNAs. Gene ontology analysis revealed many of these transcripts are linked to mRNA processing and RNA splicing (FDR<0.05) e.g., CLK3 splicing factor kinase, Y-Box protein 1, and DEAD-box Helicase 5. Thus, DDX41-regulated splicing is associated with regulation of alternative splicing of transcripts encoding splicing regulators.
YBX1 is a multifunctional RNA/DNA binding protein implicated in RNA splicing (Perner et al. Leukemia 2022). Importantly, YBX1 is directly phosphorylated by myeloproliferative neoplasm-causing mutant JAK2 (Jayavelu et al. Nature 2020). We tested whether YBX1 has fundamentally important functions in erythroid cells e.g., to control cellular proliferation. DDX41, but not pathogenic variants, induces a short RNA isoform of Ybx1 lacking a conserved domain critical for Y-box protein function. DDX41 induces this short form in G1E-Ddx41+/- cells 8-fold (p=0.009). We innovated an erythroid cell model and rescue assay to assess the activities of wild-type and short-isoform YBX1, and functional analyses are ongoing. Our global mechanistic analyses revealed that DDX41-regulated splicing commonly requires CLK3 (Kim et al. Nature Commun. 2025). We are conducting comparable studies to establish if YBX1 is a determinant of DDX41-regulated splicing at all or a subset of RNA targets.
In summary, we demonstrated that DDX41 regulates alternative splicing of multiple splicing regulators including Clk3 and Ybx1, these activities are conserved among multiple cell types, and quantifying splicing of these transcripts can rigorously discriminate between two benign and two pathogenic DDX41 variants. We are asking if the alternative splicing regulation can be extended to human patient specimens as part of our strategy to innovate a minimalistic toolkit that discriminates benign vs pathogenic DDX41 variants for high-fidelity clinical curation.
DISCLOSURES
Christina Maria Jurotich, BS: No relevant conflicts of interest to declare.